COVID-19 Immunization Update Masterclass: Advise, Protect, Prevent in Winter 2023Thursday, 28 September 2023 | 17:00 CETFOR HEALTHCARE PROFESSIONALS ONLYThe Nuvaxovid™ ▼ COVID-19 Vaccine (recombinant, adjuvanted)—also known as NVX-CoV2373—has been granted marketing authorisation in the European Union for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The vaccine should be used in accordance with official recommendations. Global information for healthcare professionals is available at: https://www.novavaxcovidvaccine.com Click here to view the EU Summary of Product Characteristics Suspected Adverse Events should be reported via the national reporting system which can be accessed at: https://www.novavaxcovidvaccine.com To learn more about our privacy practices, please view our privacy policy. |